New immune data from the ongoing phase 2 trial with EVX-01 will be presented at a poster session tomorrow at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago.

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat ...

Infectimune® studies funded by and performed by investigators at the National Institute of Allergy and Infectious Diseases (NIAID)’s Center for Influenza Vaccine Research for High-Risk Populations ...

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, ...

Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 ...

With a new wave of serums claiming to extend our skin cells' lifespan, can these products help us better understand what lies ...